AstraZeneca Study Results Put Iressa on Ice; Will New EGFR Diagnostics Save It? | GenomeWeb

A targeted-medicine hopeful is in trouble.

After reviewing recent data showing no survival benefit for patients taking the cancer drug Iressa, the US Food and Drug Administration this week urged current consumers of the drug to see their doctors and consider changing prescriptions, a development that may spell the end of the drug unless responders can be reliably identified. The company’s manufacturer, AstraZeneca, is currently discussing the drug’s fate with the FDA.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.